More specifically, we demonstrate the feasibility of fully automated radiation dose estimation in unsealed source therapy as applied to patients with metastatic prostate cancer treated with radioactive prostate-specific membrane antigen (PSMA). This evidence concerns the gene FOLH1 and metastatic prostate carcinoma.